Conmed to exit gastroenterology product lines

Conmed (CNMD) announced its intention to exit its gastroenterology product lines as part of its broader portfolio optimization strategy. This exit allows Conmed to fully align operations and resources within its core markets. “Today’s announcement reflects a positive step in our strategic portfolio review and our commitment to focus on areas where CONMED can lead in innovation and deliver the greatest impact- minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair,” said Patrick Beyer, Conmed’s president and CEO. “By concentrating our resources on our core growth platforms, we are positioning CONMED for long-term success and continued leadership in surgical innovation. We are proud of the contributions our gastroenterology team has made to advancing patient care and supporting clinicians over the years, and we thank them for their dedication and impact on the business.”